

IAP5 Rec'd PCT/PTO 01 AUG 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	August 1, 2006
				First Named Inventor	Tomohiko Sato
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	L7350.0010

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AMG/	CA	Koji Itahana, et al., Tumor Suppressor ARF Degrades B23, a Nucleolar Protein Involved in Ribosome Biogenesis and Cell Proliferation, Molecular Cell, 2003, Vol. 12, pages 1151-64.	
/AMG/	CB	Peter Brzovic, et al., Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex, PNAS, 2003, vol100, no. 10, pages 5646-51.	
/AMG/	CC	Rintaro Hashizume, et al., The Ring Heterodimer BRCA1-BARD1 is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation, The Journal of Biological Chemistry, 2001, Vol. 276, No. 18, pgs 14537-14540.	
/AMG/	CD	Ko Sato, et al., Nucleophosmin/B23 is a Candidate Substrate for the BRCA1-BARD1 Ubiquitin Ligase, The Journal of Biological Chemistry, 2004, Vol. 279, No. 30, pgs 30919-22	
/AMG/	CE	Ryosuke Hayami, et al., Down-regulation of BRCA1-BARD1 Ubiquitin Ligase by CDK2, Cancer Res., 2005, Vol. 65, No. 1, pages 6-10.	
/AMG/	CF	H. Wang, et al., BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases, Oncogene, 1997, Vol. 15, pgs 143-157.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Anne M. Gussow/	Date Considered	03/04/2008
--------------------	------------------	-----------------	------------